Early and Visible Improvements after Application of K101 in the Appearance of Nails Discoloured and Deformed by Onychomycosis
- 1
- 2
- 3
Abstract
Onychomycosis is a fungal infection of the nails of the fingers and toes and is difficult to cure. A previous 24-week, placebo-controlled study demonstrated that a solution containing propylene glycol, urea and lactic acid (K101) was well-tolerated and effective in the treatment of onychomycosis. Patients who received K101 judged that their condition had improved from Week 2 of treatment onwards. The aim of the current study was to further evaluate and document early visible effects on nail appearance after application of topical K101 in an 8-week baseline-controlled study in 75 patients. Patients graded the appearance of their nail compared with baseline using a four-point scale. Compared with baseline, 91.8% (67/73; 95% confidence interval (CI): 83.0%, 96.9%) of the patients experienced at least some improvement in their target nail after 8 weeks of treatment. At Week 2, the proportion showing some improvement was 76.7% (56/73; 95% CI: 65.4%, 85.8%) with this number increasing to 87.7% (64/73; 95% CI: 77.9%, 94.2%) at Week 4. Proportions of patients reporting less thickened, less discoloured, less brittle and softer nails increased over the course of the study. No safety issues were identified. In conclusion, K101 provided early visible improvements in nails affected by onychomycosis.
- B. E. Elewski and M. A. Charif, “Prevalence of Onychomycosis in Patients Attending a Dermatology Clinic in Northeastern Ohio for Other Conditions,” Archives of Dermatology, Vol. 133, No. 9, 1997, pp. 1172-1173. doi.org/10.1001/archderm.133.9.1172
- A. K. Gupta, N. Konnikov, P. MacDonald, P. Rich, N. W. Rodger, M. W. Edmonds, et al., “Prevalence and Epidemiology of Toenail Onychomycosis in Diabetic Subjects: A Multicentre Survey,” British Journal of Dermatology, Vol. 139, No. 4, 1998, pp. 665-671. doi.org/10.1046/j.1365-2133.1998.02464.x
- E. L. Svejgaard and J. Nilsson, “Onychomycosis in Denmark: Prevalence of Fungal Nail Infection in General Practice,” Mycoses, Vol. 47, No. 3-4, 2004, pp. 131-135.
- B. Elewski, “Onychomycosis: Pathogenesis, Diagnosis, and Management,” Clinical Microbiology Reviews, Vol. 11, No. 3, 1998, pp. 415-429.
- D. de Berker, “Clinical Practice. Fungal Nail Disease,” New England Journal of Medicine, Vol. 360, No. 20, 2009, pp. 2108-2116. doi.org/10.1056/NEJMcp0804878
- A. K. Gupta, M. Uro and E. A. Cooper, “Onychomycosis Therapy: Past, Present, Future,” Journal of Drugs in Dermatology, Vol. 9, No. 9, 2010, pp. 1109-1113.
- O. Welsh, L. Vera-Cabrera and E. Welsh, “Onychomycosis,” Clinics in Dermatology, Vol. 28, No. 2, 2010, pp. 151-159. doi.org/10.1016/j.clindermatol.2009.12.006
- D. P. O’Sullivan, C. A. Needham, A. Bangs, K. Atkin and F. D. Kendall, “Postmarketing Surveillance of Oral Terbinafine in the UK: Report of a Large Cohort Study,” British Journal of Clinical Pharmacology, Vol. 42, No. 5, 1996, pp. 559-565.
- J. Faergemann and G. Swanbeck, “Treatment of Onychomycosis with a Propylene Glycol-Urea-Lactic Acid Solution,” Mycoses, Vol. 32, No. 10, 1989, pp. 536-540. doi.org/10.1111/j.1439-0507.1989.tb02178.x
- L. Emtestam, T. Kaaman and K. Rensfeldt, “Treatment of Distal Subungual Onychomycosis with a Topical Preparation of Urea, Propylene Glycol and Lactic Acid: Results of a 24-Week, Double-Blind, Placebo-Controlled Study,” Unpublished.
- S. Nolting, J. Carazo, K. Boulle and J. R. Lambert, “Oral Treatment Schedules for Onychomycosis: A Study of Patient Preference,” International Journal of Dermatology, Vol. 37, No. 6, 1998, pp. 454-456. doi.org/10.1046/j.1365-4362.1998.00357.x
- Y. Hu, L. Yang, L. Wei, X. Y. Dai, H. K. Hua, J. Qi, et al., “Study on the Compliance and Safety of the Oral Antifungal Agents for the Treatment of Onychomycosis,” Zhonghua Liu Xing Bing Xue Za Zhi, Vol. 26, No. 12, 2005, pp. 988-991.